Nathan D Adams

US Patent:

6352980, Mar 5, 2002

Filed:

Sep 21, 1999

Appl. No.:

09/399977

Inventors:

David L. Berliner - Atherton CA
Nathan W. Adams - Salt Lake City UT
Clive L. Jennings-White - Salt Lake City UT

Assignee:

Pherin Pharmaceuticals, Inc. - Mountain View CA

International Classification:

A61K 3156

US Classification:

514169, 514170, 514177, 514178, 514182

Abstract:

The invention relates to estrene steroids, which bind to neuroepithelial receptors. The steroid is preferably administered in the form of a pharmaceutical composition containing one or more pharmaceutically acceptable carriers.

US Patent:

20020103391, Aug 1, 2002

Filed:

Mar 9, 2001

Appl. No.:

09/803378

Inventors:

David Berliner - Atherton CA, US
Nathan Adams - Salt Lake City UT, US
Clive Jennings-White - Salt Lake City UT, US

International Classification:

C07J013/00
C07J003/00

US Classification:

552/530000, 552/610000, 552/611000

Abstract:

The invention relates to novel, androstane steroids which are the ligand semiochemicals which bind to neuroepithelial receptors.

US Patent:

20020143001, Oct 3, 2002

Filed:

Aug 3, 2001

Appl. No.:

09/922216

Inventors:

David Berliner - Atherton CA, US
Nathan Adams - Salt Lake City UT, US
Clive Jennings-White - Salt Lake City UT, US

International Classification:

A61K031/56

US Classification:

514/182000, 514/179000

Abstract:

The invention relates to a method of altering hypothalamic function in an individual. The method comprises nasally administering a human semiochemical, e.g. an Androstane steroid, or a pharmaceutical composition containing a semiochemical, such that the ligand semiochemical binds to a specific neuroepithelial receptor. The steroid or steroids is/are preferably administered in the form of a pharmaceutical composition containing one or more pharmaceutically acceptable carriers. Other embodiments of the invention include pharmaceutical compositions containing the steroids.

US Patent:

59691689, Oct 19, 1999

Filed:

Sep 29, 1994

Appl. No.:

8/316435

Inventors:

David L. Berliner - Atherton CA
Nathan W. Adams - Salt Lake City UT
Clive L. Jennings-White - Salt Lake City UT

Assignee:

Pherin Corporation - Menlo Park CA

International Classification:

C07J 300
C07J 100

US Classification:

552611

Abstract:

The invention relates to novel, androstane steroids which are the ligand semiochemicals which bind to neuroepithelial receptors. The steroids are useful as ligands to neuroepithelial receptors in the human vomeronasal gland to stimulate autonomic and hypothalamic activity.

US Patent:

57835713, Jul 21, 1998

Filed:

Sep 28, 1993

Appl. No.:

8/127980

Inventors:

David L. Berliner - Atherton CA
Nathan William Adams - Salt Lake City UT
Clive L. Jennings-White - Salt Lake City UT

Assignee:

Pherin Corporation - Menlo Park CA

International Classification:

A61K 3156

US Classification:

514177

Abstract:

The invention relates to a method of altering hypothalamic function in an individual. The method comprises nasally administering a human semiochemical, e. g. an Estrene steroid, or a pharmaceutical composition containing an Estrene steroid, such that the ligand semiochemical binds to a specific neuroepithelial receptor. The steroid is preferably administered in the form of a pharmaceutical composition containing one or more pharmaceutically acceptable carriers. Other embodiments of the invention include pharmaceutical compositions containing the steroids.

US Patent:

59945680, Nov 30, 1999

Filed:

Jun 6, 1995

Appl. No.:

8/469197

Inventors:

David L. Berliner - Atherton CA
Nathan W. Adams - Salt Lake City UT
Clive L. Jennings-White - Salt Lake City UT

Assignee:

Pherin Corporation - Menlo Park CA

International Classification:

C07J 5300
C07J 100

US Classification:

552502

Abstract:

The invention relates to estrene steroids, which bind to neuroepithelial receptors. The steroid is preferably administered in the form of a pharmaceutical composition containing one or more pharmaceutically acceptable carriers.

US Patent:

58830871, Mar 16, 1999

Filed:

May 28, 1996

Appl. No.:

8/654021

Inventors:

David L. Berliner - Atherton CA
Nathan William Adams - Salt Lake City UT
Clive L. Jennings-White - Salt Lake City UT

Assignee:

Pherin Corporation - Menlo Park CA

International Classification:

A61K 31565

US Classification:

514182

Abstract:

The invention relates to a method of altering hypothalamic function in an individual. The method comprises nasally administering a human semiochemical, e. g. an Androstane steroid, or a pharmaceutical composition containing a semiochemical, such that the ligand semiochemical binds to a specific neuroepithelial receptor. The steroid or steroids is/are preferably administered in the form of a pharmaceutical composition containing one or more pharmaceutically acceptable carriers. Other embodiments of the invention include pharmaceutical compositions containing the steroids.

US Patent:

59655526, Oct 12, 1999

Filed:

Dec 15, 1998

Appl. No.:

9/212735

Inventors:

David L. Berliner - Atherton CA
Nathan William Adams - Salt Lake City UT
Clive L. Jennings-White - Salt Lake City UT

Assignee:

Pherin Pharmaceuticals, Inc. - Menlo Park CA

International Classification:

A61K 31565

US Classification:

514182

Abstract:

The invention relates to a method of altering hypothalamic function in an individual. The method comprises nasally administering a human semiochemical, e. g. an Androstane steroid, or a pharmaceutical composition containing a semiochemical, such that the ligand semiochemical binds to a specific neuroepithelial receptor. The steroid or steroids is/are preferably administered in the form of a pharmaceutical composition containing one or more pharmaceutically acceptable carriers. Other embodiments of the invention include pharmaceutical compositions containing the steroids.